Unfractionated gliadin and its alpha-, beta-, gamma- and omega-gliadin subfractions were used as rabbit immunogens. The antisera were characterized by (1) Ouchterlony double diffusion, (2) binding of 125I-labelled gliadin subfractions, (3) inhibition by several gliadin subfractions of binding between gamma-gliadin antiserum and 125I-labelled gamma-gliadin. Double diffusion showed identical cross-reactivity between the antisera and the gliadin subfractions with the exception of omega-gliadin. Precipitin lines of partial identity with gliadin were observed against rye secalins and barley hordeins but not oat avenins or maize zeins. Binding was observed between unfractionated 125I-labelled alpha-, beta-, gamma- and omega-gliadins and all the antisera. There was binding of 125I-labelled omega-gliadin to the omega-gliadin antiserum but poor binding of 125I-labelled omega-gliadin to unfractionated alpha-, beta- and gamma-gliadin antisera. Competitive inhibition of binding between 125I-labelled gamma-gliadin and gamma-gliadin antiserum diluted 1:250 (v/v) demonstrated similar competition between alpha-, beta- and gamma-gliadins and this antiserum but poor competition between omega-gliadin, wheat glutenins, albumins and globulins, rye secalins, barley hordeins and oat avenins. These findings suggest that there is a good correlation between the antigenic structure of gliadin proteins and their toxicity to patients with coeliac disease.
No takes yet. Share an insight, caveat, or question.
Ciclitira et al. (1985) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: